Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| 5'-Nucleotidase (CD73 or Ecto-5'-Nucleotidase or EC 3.1.3.5) Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| 5'-Nucleotidase (CD73 or Ecto-5'-Nucleotidase or EC 3.1.3.5) Products under Development by Stage of Development | 7 | 1 |
| 5'-Nucleotidase (CD73 or Ecto-5'-Nucleotidase or EC 3.1.3.5) Products under Development by Therapy Area | 8 | 1 |
| 5'-Nucleotidase (CD73 or Ecto-5'-Nucleotidase or EC 3.1.3.5) Products under Development by Indication | 9 | 1 |
| 5'-Nucleotidase (CD73 or Ecto-5'-Nucleotidase or EC 3.1.3.5) Pipeline Products Glance | 10 | 1 |
| Early Stage Products | 10 | 1 |
| 5'-Nucleotidase (CD73 or Ecto-5'-Nucleotidase or EC 3.1.3.5) Products under Development by Companies | 11 | 2 |
| 5'-Nucleotidase (CD73 or Ecto-5'-Nucleotidase or EC 3.1.3.5) Products under Development by Universities/Institutes | 13 | 2 |
| 5'-Nucleotidase (CD73 or Ecto-5'-Nucleotidase or EC 3.1.3.5) Therapeutics Assessment | 15 | 6 |
| Assessment by Monotherapy/Combination Products | 15 | 1 |
| Assessment by Mechanism of Action | 16 | 1 |
| Assessment by Route of Administration | 17 | 2 |
| Assessment by Molecule Type | 19 | 2 |
| 5'-Nucleotidase (CD73 or Ecto-5'-Nucleotidase or EC 3.1.3.5) Companies Involved in Therapeutics Development | 21 | 4 |
| Corvus Pharmaceuticals, Inc. | 21 | 1 |
| Innate Pharma S.A. | 22 | 1 |
| MedImmune, LLC | 23 | 1 |
| Vitae Pharmaceuticals, Inc. | 24 | 1 |
| 5'-Nucleotidase (CD73 or Ecto-5'-Nucleotidase or EC 3.1.3.5) Drug Profiles | 25 | 8 |
| Antibody to Inhibit CD73 for Oncology Drug Profile | 25 | 1 |
| durvalumab + MEDI-9447 Drug Profile | 26 | 1 |
| MEDI-9447 Drug Profile | 27 | 1 |
| Monoclonal Antibody to Inhibit CD73 for Cancer Drug Profile | 28 | 1 |
| Monoclonal Antibody to Inhibit CD73 for Oncology Drug Profile | 29 | 1 |
| Monoclonal Antibody to Inhibit CD73 for Oncology Drug Profile | 30 | 1 |
| Small Molecules to Inhibit CD73 for Oncology Drug Profile | 31 | 1 |
| Small Molecules to Inhibit CD73 for Oncology Drug Profile | 32 | 1 |
| 5'-Nucleotidase (CD73 or Ecto-5'-Nucleotidase or EC 3.1.3.5) Featured News &Press Releases | 33 | 2 |
| Apr 18, 2016: Innate Pharma presents new CD73 checkpoint inhibitor program | 33 | 1 |
| Feb 24, 2014: CD73 Research Could Lead to Cancer Drug | 33 | 2 |
| Appendix | 35 | 2 |
| Methodology | 35 | 1 |
| Coverage | 35 | 1 |
| Secondary Research | 35 | 1 |
| Primary Research | 35 | 1 |
| Expert Panel Validation | 35 | 1 |
| Contact Us | 35 | 1 |
| Disclaimer | 36 | 1 |